Every Form 4 that Atea Pharmaceuticals, Inc. (AVIR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AVIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVIR filings page.
Atea Pharmaceuticals director Bruno Lucidi reported equity compensation activity centered on stock awards rather than open‑market trades. He exercised 29,600 restricted stock units into Common Stock and held 142,350 Common shares directly afterward. He also received 37,700 stock options with a $4.36 exercise price and 26,700 new restricted stock units, all subject to time‑based vesting over the coming year.
Atea Pharmaceuticals director Franklin M. Berger increased his equity exposure through compensation-related awards and an RSU vesting event. On June 18, 2026, 29,600 restricted stock units converted into an equal number of common shares, bringing his direct common stock holdings to 536,097 shares.
He also received a stock option for 37,700 shares at an exercise price of $4.36 per share, vesting in twelve equal monthly installments after June 18, 2026, and expiring on June 17, 2036. In addition, he was granted 26,700 new restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Howard Berman received new equity awards as part of his compensation. On June 18, 2026, he was granted stock options covering 37,700 shares of common stock at an exercise price of $4.36 per share. These options vest in twelve substantially equal monthly installments after June 18, 2026, and are fully vested on June 18, 2027, if he continues serving the company.
He also received 26,700 restricted stock units, each representing a contingent right to one share of common stock. The RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Barbara Gayle Duncan increased her equity stake through routine compensation-related transactions. On June 18, 2026, previously granted restricted stock units converted into 29,600 shares of common stock, bringing her direct holdings to 92,350 shares.
She also received new grants covering 37,700 stock options with a $4.36 exercise price, vesting in twelve equal monthly installments through June 18, 2027, and 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.
Atea Pharmaceuticals director Bruce Polsky reported routine equity compensation changes. On June 18, 2026, he exercised 29,600 restricted stock units into Common Stock at no cost, bringing his direct Common Stock holdings to 124,806 shares.
He also received new awards: a stock option for 37,700 shares of Common Stock at an exercise price of $4.36 per share, vesting in twelve equal monthly installments after June 18, 2026, and 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, in each case subject to continued service. The filing shows no share sales, only grants and exercises related to compensation.
Atea Pharmaceuticals director Polly A. Murphy reported equity compensation activity and an RSU vesting-related share delivery. On June 18, 2026, RSUs covering 29,600 shares of common stock were exercised into common stock, leaving her with 121,745 common shares directly held.
On the same date, she received a stock option grant for 37,700 shares of common stock at an exercise price of $4.36 per share, vesting in twelve substantially equal monthly installments through June 18, 2027, and expiring on June 17, 2036. She was also granted 26,700 restricted stock units, each representing one share of common stock, vesting in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.
Atea Pharmaceuticals director Jerome M. Adams reported equity compensation and a routine derivative exercise. On June 18, 2026, he exercised 29,600 shares of previously granted restricted stock units into Common Stock, leaving him with 92,350 Common shares held directly.
On the same date, he received a new grant of 37,700 stock options with a $4.36 exercise price, expiring on June 17, 2036, which vest in twelve equal monthly installments after June 18, 2026. He was also granted 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to his continued service.
Atea Pharmaceuticals director Arthur S. Kirsch received new equity awards. He was granted stock options covering 37,700 shares of common stock at an exercise price of $4.36 per share. These options vest in twelve substantially equal monthly installments after June 18, 2026 and are fully vested by June 18, 2027, subject to his continued service.
Kirsch also received 26,700 restricted stock units, each representing a contingent right to one share of common stock. These RSUs vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, conditioned on continued service through the vesting date.
Atea Pharmaceuticals director Polly A. Murphy reported an open-market purchase of 6,100 shares of Common Stock on May 18, 2026 at a weighted average price of $4.1715 per share. Following this trade, she directly owns 92,145 shares of Atea Pharmaceuticals.
The shares were bought in multiple transactions at prices ranging from $4.14 to $4.19 per share. This Form 4/A amends a prior Form 4 only to correct the transaction date, which had been mistakenly reported as May 18, 2025 instead of May 18, 2026.
Atea Pharmaceuticals director Polly A. Murphy reported an open-market purchase of 6,100 shares of Common Stock. The shares were bought on May 18, 2025 at a weighted average price of $4.1715 per share, with individual trade prices ranging from $4.14 to $4.19 per share. Following this transaction, Murphy directly holds 92,145 shares of Atea Pharmaceuticals common stock.
Atea Pharmaceuticals, Inc. officer Andrea Corcoran exercised stock options to acquire 60,000 shares of common stock at an exercise price of $1.2400 per share. The option was fully vested and exercisable. Following the transaction, she directly holds 823,576 shares of Atea common stock.
Atea Pharmaceuticals Chief Medical Officer Maria Arantxa Horga reported equity compensation activity involving common stock, restricted stock units (RSUs), and stock options. On January 31, 2026, 41,533 RSUs from a 124,600-unit grant and an additional 9,750 performance-based RSUs vested and were converted into common shares, after which no RSUs remained outstanding from these grants.
On the same date, 51,283 shares of common stock were acquired through an option or RSU-related transaction, and 16,073 shares of common stock were disposed of at $4.24 per share, leaving 96,086 common shares beneficially owned directly. Horga also received a new stock option for 173,500 shares at an exercise price of $4.24, vesting in 48 equal monthly installments starting after January 31, 2026 and becoming fully vested on January 31, 2030.
Atea Pharmaceuticals Chief Commercial Officer John Vavricka reported several equity transactions in the company’s stock. On January 31, 2026, he acquired 42,083 shares of common stock through the vesting and settlement of restricted stock units.
To cover tax obligations, 11,570 shares of common stock were withheld at a price of $4.24 per share, leaving him with 82,594 directly held shares. He also holds 82,508 shares indirectly as trustee of the John F. Vavricka Deed of Trust.
On the same date, Vavricka received a new grant of 119,520 stock options with a $4.24 exercise price. These options vest in 48 equal monthly installments after January 31, 2026 and will be fully vested by January 31, 2030.
Atea Pharmaceuticals Chief Development Officer Janet Hammond reported multiple equity award transactions. On January 31, 2026, 58,050 shares of common stock were acquired through RSU conversions, with 14,136 shares withheld at $4.24 per share to cover taxes, leaving 127,665 common shares directly held.
Concurrent with this, 46,800 RSUs from a 140,400-unit grant that fully vested by January 31, 2026, and 11,250 performance-based RSUs were settled into common stock, reducing RSU holdings to zero. Hammond also received a stock option for 177,000 shares at an exercise price of $4.24 per share, vesting in 48 equal monthly installments after January 31, 2026, and fully vesting on January 31, 2030.
Atea Pharmaceuticals officer Andrea Corcoran reported equity compensation activity. On January 31, 2026, previously granted restricted stock units converted into 54,866 shares of Atea common stock at no cash cost. To cover taxes, 16,104 of these shares were withheld at a price of $4.24 per share.
After these transactions, Corcoran directly owned 763,576 Atea common shares. She also received a new stock option covering 180,000 shares at an exercise price of $4.24 per share. This option vests in 48 equal monthly installments after January 31, 2026 and is fully vested by January 31, 2030.
Atea Pharmaceuticals President, CEO, and Chairman Jean-Pierre Sommadossi reported multiple equity award settlements and an option exercise. On January 31, 2026, 173,466 restricted stock units and 99,517 performance-based RSUs converted into common stock as previously granted awards fully vested.
Also on January 31, 2026, 106,093 shares of common stock were withheld at $4.24 per share to cover tax obligations, leaving 467,830 directly held shares. On February 3, 2026, he exercised a fully vested stock option for 300,000 shares at an exercise price of $1.24 per share, increasing his direct holdings to 767,830 shares. The filing also shows 5,866,025 shares held indirectly through JPM Partners LLC.
Atea Pharmaceuticals EVP and Chief Accounting Officer Wayne Foster reported equity compensation and related share activity. On January 31, 2026, 33,333 and 8,000 restricted stock units (RSUs) converted into an equal number of Atea common shares as vesting and performance conditions were met.
Following these conversions (coded M), Foster held 91,461 common shares before tax withholding. A separate transaction (code F) shows 12,132 shares withheld at $4.24 per share to cover taxes, leaving 79,329 common shares held directly.
Foster also received a new stock option grant for 108,000 shares at a $4.24 exercise price. The option vests in forty‑eight equal monthly installments after January 31, 2026, becoming fully vested on January 31, 2030, with 108,000 options beneficially owned directly after the grant.